Home 2021

Archives

inflammatory bowel diseases

Changing the treatment paradigm in Inflammatory Bowel Diseases

Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, explains why drug-candidate ABX464 has the potential to address the urgent need for new, safe short- and long-term effective drugs to treat Inflammatory Bowel Diseases.

Follow Us

Advertisements